Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice
The advent of imatinib mesilate, an oral target therapy, has dramatically changed the natural history of gastrointestinal stromal tumours (GISTs). This rare neoplasm has become the paradigm of targeted therapies in solid tumours, also introducing a home-based cure concept in oncology. However, it should be retained that oral drug administration entails new and relevant management problems. Multiple studies have demonstrated the efficacy of imatinib in GISTs associated with a good toxicity profile. However, the efficacy of imatinib, according to its mechanism of action and pharmacokinetics, is closely related to daily assumption. No interruption or “jerky” assumption is permitted in order to avoid efficacy loss. Thus, the issue of treatment adherence is crucial for a successful strategy and should not be overlooked. We think that dealing with the problem means assessing a wide spectrum of not only clinical and general but also psychological and individual aspects. Furthermore, both patient and family should play an active role in the “cure process” and physicians should reduce the distance separating them from their patients due to home-based target therapy, promoting communication and consolidation of a trust-based physician–patient relationship. Several advantages have been introduced by oral target therapies in oncology. However, chronic drug administration, even if generally well tolerated, when prolonged for an undetermined time could heavily impact on patients’ quality of life. This could induce non-prescribed drug suspension, with negative impact on disease control. More studies would be necessary in order to detect real patients’ adherence, to correlate drug assumption with clinical outcome and to optimize imatinib treatment strategy.
KeywordsAdherence to treatment Gastrointestinal stromal tumours Imatinib mesilate Oral target therapy
The authors thank all members of the Gist Study Group Bologna (www.giststudygroup.it).
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Edmonson JH, Marks RS, Buckner JC, Mahoney MR (2002) Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 20(5–6):605–612PubMedCrossRefGoogle Scholar
- 3.Morishima Y, Ogura M, Nishimura M, Yazaki F, Bessho M, Mizoguchi H, Chiba S, Hirai H, Tauchi T, Urabe A, Takahashi M, Ohnishi K, Yokozawa T, Emi N, Hirano M, Shimazaki C, Nakao S, Kawai Y, Fujimoto M, Taguchi H, Jinnai I, Ohno R (2004) Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study. Int J Hematol 80(3):261–266PubMedCrossRefGoogle Scholar
- 6.Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480PubMedCrossRefGoogle Scholar
- 7.Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4):626–632PubMedCrossRefGoogle Scholar
- 8.Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25(9):1107–1113PubMedCrossRefGoogle Scholar
- 9.Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A, Emile JF, Chabaud S, Pérol D, Blay JY, French Sarcoma Group (2010) Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11(10):942–949PubMedCrossRefGoogle Scholar
- 10.Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22):5401–5411PubMedCrossRefGoogle Scholar
- 12.World Health Organization (2003) Adherence to long-term therapies: evidence for action. World Health Organisation, GenevaGoogle Scholar
- 14.Farmer A, Hardeman W, Hughes D, Prevost AT, Kim Y, Craven A, Oke J, Boase S, Selwood M, Kellar I, Graffy J, Griffin S, Sutton S, Kinmonth AL (2012) An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes. BMC Fam Pract 13(1):30PubMedCrossRefGoogle Scholar
- 16.Luersen K, Davis SA, Kaplan SG, Abel TD, Winchester WW, Feldman SR (2012) Sticker charts: a method for improving adherence to treatment of chronic diseases in children. Pediatr Dermatol 4. doi: 10.1111/j.1525-1470.2012.01741.x
- 17.DeMatteo RP, Owzar K, Maki R, Pisters P, Blackstein M, Antonescu C, Blanke C, Demetri G, von Mehren M, Ballman K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team (2007) Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. J Clin Oncol 25:10079Google Scholar
- 18.National Cancer Institute (2009) Imatinib mesylate or observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor. http://clinicaltrials.gov/show/NCT00103168. Accessed 15 Aug 2010
- 19.Scandinavian Sarcoma Group (2005) Study comparing 12 months versus 36 months of imatinib in the treatment of gastrointestinal stromal tumor (GIST). http://clinicaltrials.gov/show/NCT00116935. Accessed 15 Aug 2010
- 20.Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307(12):1265–1272PubMedCrossRefGoogle Scholar